vs

Side-by-side financial comparison of Prelude Therapeutics Inc (PRLD) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.

TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $6.5M, roughly 1.8× Prelude Therapeutics Inc). On growth, Prelude Therapeutics Inc posted the faster year-over-year revenue change (116.7% vs 11.9%).

PRLD vs TACT — Head-to-Head

Bigger by revenue
TACT
TACT
1.8× larger
TACT
$11.5M
$6.5M
PRLD
Growing faster (revenue YoY)
PRLD
PRLD
+104.7% gap
PRLD
116.7%
11.9%
TACT

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
PRLD
PRLD
TACT
TACT
Revenue
$6.5M
$11.5M
Net Profit
$-19.7M
Gross Margin
47.6%
Operating Margin
-314.1%
-10.1%
Net Margin
-303.5%
Revenue YoY
116.7%
11.9%
Net Profit YoY
38.9%
EPS (diluted)
$-0.26
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRLD
PRLD
TACT
TACT
Q4 25
$11.5M
Q3 25
$6.5M
$13.2M
Q2 25
$13.8M
Q1 25
$13.1M
Q4 24
$10.2M
Q3 24
$3.0M
$10.9M
Q2 24
$11.6M
Q1 24
$10.7M
Net Profit
PRLD
PRLD
TACT
TACT
Q4 25
Q3 25
$-19.7M
$15.0K
Q2 25
$-143.0K
Q1 25
$19.0K
Q4 24
Q3 24
$-32.3M
$-551.0K
Q2 24
$-319.0K
Q1 24
$-1.0M
Gross Margin
PRLD
PRLD
TACT
TACT
Q4 25
47.6%
Q3 25
49.8%
Q2 25
48.2%
Q1 25
48.7%
Q4 24
44.2%
Q3 24
48.1%
Q2 24
52.7%
Q1 24
52.6%
Operating Margin
PRLD
PRLD
TACT
TACT
Q4 25
-10.1%
Q3 25
-314.1%
0.1%
Q2 25
-1.9%
Q1 25
-0.1%
Q4 24
-10.3%
Q3 24
-1145.9%
-7.7%
Q2 24
-3.8%
Q1 24
-12.2%
Net Margin
PRLD
PRLD
TACT
TACT
Q4 25
Q3 25
-303.5%
0.1%
Q2 25
-1.0%
Q1 25
0.1%
Q4 24
Q3 24
-1075.7%
-5.1%
Q2 24
-2.8%
Q1 24
-9.7%
EPS (diluted)
PRLD
PRLD
TACT
TACT
Q4 25
$-0.11
Q3 25
$-0.26
$0.00
Q2 25
$-0.01
Q1 25
$0.00
Q4 24
$-0.80
Q3 24
$-0.43
$-0.06
Q2 24
$-0.03
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRLD
PRLD
TACT
TACT
Cash + ST InvestmentsLiquidity on hand
$55.0M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$58.5M
$31.1M
Total Assets
$94.8M
$44.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRLD
PRLD
TACT
TACT
Q4 25
$20.4M
Q3 25
$55.0M
$20.0M
Q2 25
$17.7M
Q1 25
$14.2M
Q4 24
$14.4M
Q3 24
$153.6M
$11.3M
Q2 24
$11.1M
Q1 24
$10.6M
Stockholders' Equity
PRLD
PRLD
TACT
TACT
Q4 25
$31.1M
Q3 25
$58.5M
$31.8M
Q2 25
$31.3M
Q1 25
$30.9M
Q4 24
$30.6M
Q3 24
$156.4M
$38.4M
Q2 24
$38.5M
Q1 24
$38.6M
Total Assets
PRLD
PRLD
TACT
TACT
Q4 25
$44.8M
Q3 25
$94.8M
$45.0M
Q2 25
$44.5M
Q1 25
$44.2M
Q4 24
$44.0M
Q3 24
$197.2M
$50.5M
Q2 24
$50.4M
Q1 24
$51.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRLD
PRLD
TACT
TACT
Operating Cash FlowLast quarter
$-19.1M
$609.0K
Free Cash FlowOCF − Capex
$589.0K
FCF MarginFCF / Revenue
5.1%
Capex IntensityCapex / Revenue
0.0%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRLD
PRLD
TACT
TACT
Q4 25
$609.0K
Q3 25
$-19.1M
$3.6M
Q2 25
$3.6M
Q1 25
$-161.0K
Q4 24
$2.4M
Q3 24
$-27.3M
$327.0K
Q2 24
$636.0K
Q1 24
$-1.5M
Free Cash Flow
PRLD
PRLD
TACT
TACT
Q4 25
$589.0K
Q3 25
$3.6M
Q2 25
$3.6M
Q1 25
$-171.0K
Q4 24
$2.4M
Q3 24
$-27.4M
$259.0K
Q2 24
$499.0K
Q1 24
$-1.6M
FCF Margin
PRLD
PRLD
TACT
TACT
Q4 25
5.1%
Q3 25
27.1%
Q2 25
25.9%
Q1 25
-1.3%
Q4 24
23.2%
Q3 24
-912.0%
2.4%
Q2 24
4.3%
Q1 24
-14.9%
Capex Intensity
PRLD
PRLD
TACT
TACT
Q4 25
0.2%
Q3 25
0.0%
0.5%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
2.1%
0.6%
Q2 24
1.2%
Q1 24
1.0%
Cash Conversion
PRLD
PRLD
TACT
TACT
Q4 25
Q3 25
242.00×
Q2 25
Q1 25
-8.47×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons